Article (Scientific journals)
Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
Scheen, André
2015In Expert Opinion on Drug Metabolism and Toxicology, 11 (6), p. 1005-20
Peer Reviewed verified by ORBi
 

Files


Full Text
2015 EO Pharmacokinetics and clinical evaluation ALO PIO D2.pdf
Publisher postprint (621.73 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
alogliptin; combined therapy; fixed-dose combination; pharmacokinetics; pioglitazone; type 2 diabetes mellitus
Abstract :
[en] INTRODUCTION: Type 2 diabetes is a complex disease with multiple defects, which generally requires a combination of several pharmacological approaches to reach glucose control targets. A unique fixed-dose combination combines a thiazolidinedione (pioglitazone) and a dipeptidyl peptidase-4 inhibitor (alogliptin). Area covered: An extensive literature search was performed to analyze the pharmacokinetics of pioglitazone and alogliptin when used separately and in combination as well as to summarize clinical and toxicological considerations about the combined therapy. Expert opinion: Pioglitazone, a potent insulin sensitizer, and alogliptin, an incretin-based agent that potentiates post-meal insulin secretion and reduces glucagon secretion, have complementary mechanisms of action. The clinical efficacy of a combined therapy is superior to any single therapy in patients treated with diet or with metformin (with or without sulphonylurea). These two drugs can be administered once daily, with or without a meal. No clinically relevant pharmacokinetic interactions between the two agents have been described and the fixed-dose combination has shown bioequivalence with alogliptin and pioglitazone given separately. Combining alogliptin with pioglitazone does not alter the safety profile of each compound. Weight gain observed with pioglitazone may be limited with the addition of alogliptin. The concern of an increased risk of heart failure remains to be better investigated.
Disciplines :
Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology
Author, co-author :
Scheen, André  ;  Université de Liège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques
Language :
English
Title :
Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
Publication date :
June 2015
Journal title :
Expert Opinion on Drug Metabolism and Toxicology
ISSN :
1742-5255
eISSN :
1744-7607
Publisher :
Informa Healthcare, United Kingdom
Volume :
11
Issue :
6
Pages :
1005-20
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 03 June 2015

Statistics


Number of views
60 (6 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
10
Scopus citations®
without self-citations
9
OpenCitations
 
7

Bibliography


Similar publications



Contact ORBi